Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor–positive metastatic breast cancer

Autor: Soley Bayraktar, Sameer Batoo, Sandeep Basu, Stefan Glück, Scott H. Okuno, Eyad Al-Hattab
Přispěvatelé: Tıp Fakültesi
Rok vydání: 2020
Předmět:
Oncology
Cancer Research
medicine.medical_specialty
medicine.drug_class
Breast Neoplasms
Ribociclib
Palbociclib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Tumor
medicine
Humans
Aromatase Inhibitor
Molecular Targeted Therapy
030212 general & internal medicine
skin and connective tissue diseases
Protein Kinase Inhibitors
neoplasms
Abemaciclib
CDK4/6 Inhibitors
Predictive biomarker
Aromatase inhibitor
business.industry
Faslodex
Disease progression
Cyclin-Dependent Kinase 4
Metastatic Breast Cancer
Cyclin-Dependent Kinase 6
General Medicine
Hormone-Receptor Positive
medicine.disease
Metastatic breast cancer
Treatment Outcome
Receptors
Estrogen
chemistry
Hormone receptor
030220 oncology & carcinogenesis
Female
Receptors
Progesterone
business
Zdroj: Future Oncology. 16:2661-2672
ISSN: 1744-8301
1479-6694
DOI: 10.2217/fon-2020-0234
Popis: There are three US FDA–approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question becomes how to choose among these agents and how to sequence them. Other areas with active investigation include identifying predictive biomarkers for the selection of patients whom may benefit more from CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression on CDK4/6 inhibitors, creating novel treatment combinations and expanding use beyond HR+/HER2- MBC. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+/HER2- MBC.
Databáze: OpenAIRE
Externí odkaz: